144 related articles for article (PubMed ID: 15209189)
1. Clinical trials referral resource. Current clinical trials of 17-AG and 17-DMAG.
Ivy PS; Schoenfeldt M
Oncology (Williston Park); 2004 May; 18(5):610, 615, 619-20. PubMed ID: 15209189
[No Abstract] [Full Text] [Related]
2. [Heat shock protein 90: novel target for cancer therapy].
Chen Y; Ding J
Ai Zheng; 2004 Aug; 23(8):968-74. PubMed ID: 15301726
[TBL] [Abstract][Full Text] [Related]
3. Cancer: the rules of attraction.
Neckers L; Lee YS
Nature; 2003 Sep; 425(6956):357-9. PubMed ID: 14508471
[No Abstract] [Full Text] [Related]
4. Heat shock protein inhibitor shows antitumor activity.
Dunn FB
J Natl Cancer Inst; 2002 Aug; 94(16):1194-5. PubMed ID: 12189221
[No Abstract] [Full Text] [Related]
5. Induction of the hypoxia-inducible factor system by low levels of heat shock protein 90 inhibitors.
Ibrahim NO; Hahn T; Franke C; Stiehl DP; Wirthner R; Wenger RH; Katschinski DM
Cancer Res; 2005 Dec; 65(23):11094-100. PubMed ID: 16322259
[TBL] [Abstract][Full Text] [Related]
6. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models.
Smith V; Sausville EA; Camalier RF; Fiebig HH; Burger AM
Cancer Chemother Pharmacol; 2005 Aug; 56(2):126-37. PubMed ID: 15841378
[TBL] [Abstract][Full Text] [Related]
7. Targeting toxic proteins for turnover.
La Spada AR; Weydt P
Nat Med; 2005 Oct; 11(10):1052-3. PubMed ID: 16211038
[No Abstract] [Full Text] [Related]
8. Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics.
Workman P
Mol Cancer Ther; 2003 Feb; 2(2):131-8. PubMed ID: 12589030
[No Abstract] [Full Text] [Related]
9. Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone.
Workman P
Cancer Lett; 2004 Apr; 206(2):149-57. PubMed ID: 15013520
[TBL] [Abstract][Full Text] [Related]
10. Hsp90 inhibitors in the clinic.
Pacey S; Banerji U; Judson I; Workman P
Handb Exp Pharmacol; 2006; (172):331-58. PubMed ID: 16610366
[TBL] [Abstract][Full Text] [Related]
11. Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond.
Georgakis GV; Younes A
Future Oncol; 2005 Apr; 1(2):273-81. PubMed ID: 16555999
[TBL] [Abstract][Full Text] [Related]
12. Potent activity of a novel dimeric heat shock protein 90 inhibitor against head and neck squamous cell carcinoma in vitro and in vivo.
Yin X; Zhang H; Burrows F; Zhang L; Shores CG
Clin Cancer Res; 2005 May; 11(10):3889-96. PubMed ID: 15897590
[TBL] [Abstract][Full Text] [Related]
13. Dihydroquinone ansamycins: toward resolving the conflict between low in vitro affinity and high cellular potency of geldanamycin derivatives.
Maroney AC; Marugan JJ; Mezzasalma TM; Barnakov AN; Garrabrant TA; Weaner LE; Jones WJ; Barnakova LA; Koblish HK; Todd MJ; Masucci JA; Deckman IC; Galemmo RA; Johnson DL
Biochemistry; 2006 May; 45(17):5678-85. PubMed ID: 16634649
[TBL] [Abstract][Full Text] [Related]
14. Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.
Chiosis G; Caldas Lopes E; Solit D
Curr Opin Investig Drugs; 2006 Jun; 7(6):534-41. PubMed ID: 16784024
[TBL] [Abstract][Full Text] [Related]
15. Heat shock protein 90 is an essential molecular chaperone for nuclear transport of glucocorticoid receptor beta.
Zhang X; Clark AF; Yorio T
Invest Ophthalmol Vis Sci; 2006 Feb; 47(2):700-8. PubMed ID: 16431970
[TBL] [Abstract][Full Text] [Related]
16. Altered states: selectively drugging the Hsp90 cancer chaperone.
Workman P
Trends Mol Med; 2004 Feb; 10(2):47-51. PubMed ID: 15106614
[TBL] [Abstract][Full Text] [Related]
17. Heat shock protein and proteasome targeting agents.
Takimoto CH; Diggikar S
Hematol Oncol Clin North Am; 2002 Oct; 16(5):1269-85. PubMed ID: 12512392
[TBL] [Abstract][Full Text] [Related]
18. The Hsp90 chaperone complex as a novel target for cancer therapy.
Goetz MP; Toft DO; Ames MM; Erlichman C
Ann Oncol; 2003 Aug; 14(8):1169-76. PubMed ID: 12881371
[TBL] [Abstract][Full Text] [Related]
19. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.
Ge J; Normant E; Porter JR; Ali JA; Dembski MS; Gao Y; Georges AT; Grenier L; Pak RH; Patterson J; Sydor JR; Tibbitts TT; Tong JK; Adams J; Palombella VJ
J Med Chem; 2006 Jul; 49(15):4606-15. PubMed ID: 16854066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
